A trial looking at hormone therapy with other treatments for prostate cancer (STAMPEDE)
This trial is comparing hormone therapy alone with a combination of hormone therapy and either zoledronic acid, docetaxel (or both), celecoxib, abiraterone or radiotherapy for prostate cancer. This trial is supported by Cancer Research UK.
Doctors often use hormone therapy to treat prostate cancer that has spread outside the prostate gland. It can work very well, but the cancer often starts to grow again at some stage. Doctors think that having other treatments at the same time as hormone therapy may work better.
In this trial, everybody will have hormone therapy as they usually would. But some will have other treatments as well. The treatments are
- A bisphosphonate called zoledronic acid (zoledronate or Zometa)
- A chemotherapy drug called docetaxel (Taxotere)
- A COX-2 inhibitor called celecoxib
- A new drug called abiraterone
- Radiotherapy to the prostate
The aim of this trial is to see which treatment is best for prostate cancer that has spread outside of the prostate gland.
Who can enter
You can enter this trial if
- You have recently been diagnosed with prostate cancer that has spread outside the prostate gland into your lymph nodes or to another part of your body
- You have recently been diagnosed with prostate cancer that has not spread outside the gland if at least 2 of the following apply to you - your prostate cancer has broken through the capsule covering the gland, you have a PSA level of 40 or above, or you have a Gleason score of 8 or above
- You have prostate cancer that has started to grow again following surgery or radiotherapy and has now either spread into your lymph nodes or to another part of your body, or you have a PSA level of 20 or more, or a PSA level above 4 if it has doubled in less than 6 months
As well as that, you must
- Be due to have hormone treatment for your prostate cancer
- Be up and about for at least half the day (performance status 0, 1 or 2)
- Have satisfactory blood test results
You cannot enter this trial if you
- Have prostate cancer that has spread to the brain
- Have had chemotherapy or any other treatment that reaches the whole body (systemic treatment) for prostate cancer
- Have any other cancer that the doctors think may affect the treatment or the trial results
- Have numbness or tingling in your hands or feet (peripheral neuropathy) unless it is very mild
- Have had surgery in the last 4 weeks
- Have a serious heart condition, high blood pressure that cannot be controlled with medication or have had a heart attack or stroke in the past
- Have a peptic ulcer, bleeding into your gut or inflammatory bowel disease
- Have already had zoledronic acid, unless it was just for a short time to treat a raised level of calcium in your blood (hypercalcaemia)
- Have already had abiraterone
- Take other medication that can affect an enzyme called CYP3A4
- Are likely to need major dental work in the next 2 years
The trial will recruit about 5,000 men all together. It is a randomised trial. The men taking part are put into treatment groups by a computer. Neither you nor your doctors will be able to decide which group you are in.
- Group A have just hormone therapy or an orchidectomy
- Group B have hormone therapy or an orchidectomy, plus zoledronic acid (zoledronate or Zometa)
- Group C have hormone therapy or an orchidectomy, plus docetaxel (Taxotere)
- Group D have hormone therapy or an orchidectomy, plus celecoxib
- Group E have hormone therapy or an orchidectomy, plus zoledronic acid and docetaxel
- Group F have hormone therapy or an orchidectomy, plus zoledronic acid and celecoxib
- Group G have hormone therapy or an orchidetomy, plus abiraterone tablets
- Group H have hormone therapy or an orchidectomy, plus radiotherapy to the prostate
Please note - By April 2011, there were enough men in groups D and F. So men joining the trial after that were not put into either of those 2 groups. In November 2011, group G opened to recruitment. And in January 2013, group H opened to recruitment for men whose cancer has spread outside the prostate. So men joining the trial since then are put into groups A, B, C, E, G or H.
All the men taking part will have hormonal treatment. This could be hormone injections, tablets or an operation to remove both testicles (an orchidectomy). The hormone testosterone is made the testicles, so if they are removed, the level of testosterone falls dramatically. Any other treatment you have will depend on which treatment group you are in.
If you are in group B or E, you have zoledronic acid as an injection into a vein once every 3 weeks for 18 weeks. Then once every 4 weeks for up to 2 years.
If you are in group C or E, you have docetaxel into a vein once every 3 weeks for 18 weeks. You also take steroid tablets called prednisolone every day during this time. If you are in group E, you will have zoledronic acid and docetaxel as separate injections on the same day, every 3 weeks for the first 18 weeks. You then have zoledronic acid every 4 weeks for up to 2 years.
If you are in group G, you have abiraterone tablets each day. You also take a steroid tablet each day. How long you take the tablets for will depend on the stage of your prostate cancer, and whether or not the treatment is helping you.
If you are in group H, you have radiotherapy either once a week for 6 weeks, or 5 times a week for 4 weeks. If you have radiotherapy 5 times a week for 4 weeks, each dose is lower than if you have it weekly, but the total dose is a bit higher.
The trial team will ask you to fill out a number of questionnaires during the trial. These ask about any side effects you have had and about how you have been feeling. This is called a quality of life study. They will also ask for an extra blood sample and a sample of tissue taken when your cancer was diagnosed. They will look at the DNA and proteins in your samples to learn more about the causes of prostate cancer and how it responds to different treatments. If you don’t want to give samples for this study, you don’t have to. You can still take part in the trial.
You will see the doctors and have some tests before you can take part in this trial. The tests include
- CT scan or MRI scan
- Bone scan
- Chest X-ray
- Heart trace (ECG)
- Blood tests (including a PSA test)
- Physical examination
How often you go to the hospital for treatment will depend on which group you are in. But everybody taking part will see the trial team
- Every 6 weeks for the first 6 months
- Every 3 months up to 2 years
- Then every 6 months up to 5 years
- Once a year after that
The most common side effects of hormone therapy or orchidectomy are
The most common side effects of zoledronic acid are
- Flu like symptoms
The most common side effects of docetaxel are
- Hair loss
- A drop in blood cells causing an increased risk of infection, bleeding or bruising problems, tiredness or breathlessness
- Swelling of hands and feet (fluid retention)
- Feeling or being sick
- Sore mouth
The most common side effects of abiraterone are
- Fluid retention
- High blood pressure
- Low levels of potassium in your blood
- Hot flushes
- A drop in the number of red blood cells (anaemia)
- Tummy (abdominal) pain
- Feeling or being sick
- Joint pain
- Diarrhoea or constipation
- Changes to the way your liver works
- An increase in the amount of sugar (glucose) in your blood
The most common side effects of radiotherapy to the prostate are
- Inflammation of the bladder
- Inflammation of the back passage (proctitis)
- Sore skin in the genital area
- Problems passing urine
- Erection problems
Location of trial
For more information
Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you need to print this page and take it to your own doctor to discuss.
Cancer Research UK
407 St John Street
This is Cancer Research UK trial number CRUK/06/019.
Rated 5 out of 5 based on 2 votes
Question about cancer? Contact our information nurse team